On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

An auto-recruit program improved DXA screening and bone health management in men with prostate cancer receiving androgen-deprivation therapy.

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...